“The data add to the body of evidence that Covaxin, an adjuvated whole SARS-CoV-2 virus inactivated vaccine, has been demonstrated to be well-tolerated and effective against COVID-19 disease,” the Nasdaq listed firm said.
from The Hindu - Telangana https://ift.tt/ojJEqYD
No comments:
Post a Comment